Lin, T.A.; Fuller, C.D.; Verma, V.; Mainwaring, W.; Espinoza, A.F.; Miller, A.B.; Jethanandani, A.; Pasalic, D.; Das, P.; Minsky, B.D.;
et al. Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers 2020, 12, 2636.
https://doi.org/10.3390/cancers12092636
AMA Style
Lin TA, Fuller CD, Verma V, Mainwaring W, Espinoza AF, Miller AB, Jethanandani A, Pasalic D, Das P, Minsky BD,
et al. Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers. 2020; 12(9):2636.
https://doi.org/10.3390/cancers12092636
Chicago/Turabian Style
Lin, Timothy A., Clifton David Fuller, Vivek Verma, Walker Mainwaring, Andres F. Espinoza, Austin B. Miller, Amit Jethanandani, Dario Pasalic, Prajnan Das, Bruce D. Minsky,
and et al. 2020. "Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials" Cancers 12, no. 9: 2636.
https://doi.org/10.3390/cancers12092636
APA Style
Lin, T. A., Fuller, C. D., Verma, V., Mainwaring, W., Espinoza, A. F., Miller, A. B., Jethanandani, A., Pasalic, D., Das, P., Minsky, B. D., Thomas, C. R., Jr., Fogelman, D. R., Subbiah, V., Subbiah, I. M., & Ludmir, E. B.
(2020). Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers, 12(9), 2636.
https://doi.org/10.3390/cancers12092636
